Risperidone for pre-existing severe tardive dyskinesia: A 48-week prospective follow-up study

International Clinical Psychopharmacology

Volumn 20, Issue 2, 2005, Pages 79-85

  Bai, Ya Mei ^a,b   Yu, Shun Chieh ^c   Chen, Jen Yeu ^b   Lin, Chih Yuan ^b   Chou, Pesus ^a   Lin, Chao Cheng ^b,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b YULI VETERANS HOSPITAL   (Taiwan)

^c Yuli Hospital Department of Health Taiwan   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atypical antipsychotics; Follow up study; Risperidone; Schizophrenia; Tardive dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RISPERIDONE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSTONIA; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; TAIWAN; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 14844346399     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200503000-00003     Document Type: Article

References (70)

1. Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, Rotrosen J (1998). Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 43:868-872.
2. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. (1999). Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 56:836-841.
3. Agarwal V, Kumar P (2001). Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases. J Clin Psychiatry 62:298-299.
4. Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR (1998). Clozapine withdrawal - emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 59:472-477.
5. Alptekin K, Kivircik BB (2002). Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. Int Clin Psychopharmacol 17:263-264.
6. Bai YM, Yu SC, Lin CC (2003). Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 64:1342-1348.
7. Bassitt DP, Souza Lobo GL (2000). Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 33:155-156.
8. Bella VL, Piccoli F (2003). Olanzepine-induced tardive dyskinesia. Br J Psychiatry 182:81-82.
9. Benazzi F (2002). Rapid onset of tardive dyskinesia in Huntington disease with olanzapine. J Clin Psychopharmacol 22:438-439.
10. Bergen J, Kitchin R, Berry G (1992). Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biol Psychiatry 32: 580-594.
11. Caroff SN, Mann SC, Campbell EC, Sullivan KA (2002). Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63 (suppl 4):12-19.
12. Casey DE (1999). Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35 (suppl):S61-S66.
13. Casey DE (2004). Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65 (suppl 9):25-28.
14. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. (1996). Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53:313-319.
15. Chen JY, Bai YM, Pyng LY, Lin CC (2001). Risperidone for tardive dyskinesia. Am J Psychiatry 158:1931-1932.
16. Chong SA, Remington G, Tan CH (1999). Risperidone treatment of tardive dyskinesia and dystonia. J Clin Psychiatry 60:340-341.
17. Chouinard G (1995). Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 15:363-443.
18. Chouinard G, Annable L, Ross-Chouinard A, Mercier P (1988). A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 8:213-263.
19. Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414-425.
20. Csernansky JG, Mahmoud R, Brenner R (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22.
21. Dave M (1994). Clozapine-related tardive dyskinesia. Biol Psychiatry 35:886-887.
22. Davidson M (2001). Long-term safety of risperidone. J Clin Psychiatry 62 (suppl 21):26-28.
23. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, et al. (2000). A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry 15:506-514.
24. Egan MF, Apud J, Wyatt RJ (1997). Treatment of tardive dyskinesia. Schizophr Bull 23:583-609.
25. Farah A (2001). Reduction of tardive dyskinesia with quetiapine. Schizophr Res 47:309-310.
26. Gardos G, Cole JO, Haskell D, Marby D, Paine SS, Moore P (1988). The natural history of tardive dyskinesia. J Clin Psychopharmacol 8:31S-37S.
27. Gerbino L (2004). Clozapine in the treatment of tardive dyskinesia: an interim report. In: Tardive Dyskinesia: Research and Treatment. New York: SP Medical and Scientific Books.
28. Gerlach J, Casey DE (1988). Tardive dyskinesia. Acta Psychiatr Scand 77: 369-378.
29. Ghaemi SN, Ko JY (2001). Quetiapine-related tardive dyskinesia. Am J Psychiatry 158:1737.
30. Ghelber D, Belmaker RH (1999). Tardive dyskinesia with quetiapine. Am J Psychiatry 156:796-797.
31. Gupta S, Mosnik D, Black DW, Berry S, Masand PS (1999). Tardive dyskinesia: review of treatments past, present, and future. Ann Clin Psychiatry 11: 257-266.
32. Hsu SY, Chang CJ, Lau SK, Lin HN (1997). Effects of risperidone therapy in a patient with tardive dyskinesia and Tardive dystonia. Taiwanese J Psychiatry 11:195-201.
33. Hyde TM, Egan MF, Brown RJ, Weinberger DR, Kleinman JE (1995). Diurnal variation in tardive dyskinesia. Psychiatry Res 56:53-57.
34. Jeste DV, Wyatt RJ (1982). Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch Gen Psychiatry 39:803-816.
35. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA (2000). Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 157:1150-1155.
36. Kane JM, Woerner M, Lieberman J (1988). Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8:52S-56S.
37. Keck ME, Muller MB, Binder EB, Sonntag A, Holsboer F (2004). Ziprasidone-related tardive dyskinesia. Am J Psychiatry 161:175-176.
38. Keepers GA, Casey DE (1991). Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 148:85-89.
39. Khan BU (1997). Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. J Autism Dev Disord 27:479-489.
40. Kinon BJ, Basson BR, Stauffer VL, Basson BR (1999). Effect of chronic olanzapine treatment on the course of presumptive tardive dyskinesia. Schizophr Res 36:363.
41. Kopala LC, Honer WG (1994). Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol 14:430-431.
42. Kucerova H (2002). Olanzapine and improvement of tardive dyskinesia. Eur Psychiatry 17:421-424.
43. Kumar S, Malone DM (2000). Risperidone implicated in the onset of tardive dyskinesia in a young woman. Postgrad Med J 76:316-317.
44. Lieberman J, Lesser M, Johns C, Pollack S, Saltz B, Kane J (1988a). Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol 8:57S-63S.
45. Lieberman J, Pollack S, Lesser M, Kane J (1988b). Pharmacologic characterization of tardive dyskinesia. J Clin Psychopharmacol 8:254-260.
46. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J (1991). The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503-510.
47. Lykouras L, Agelopoulos E, Tzavellas E (2002). Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 26:815-817.
48. Megna JL, Dewan M (1999). A naturalistic study of risperidone maintenance treatment of outpatients with severe mental illness. Psychiatr Serv 50: 1084-1086.
49. Meltzer HY, Matsubara S, Lee JC (1989). The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392.
50. Morgenstern H, Glazer WM, Woods SW (2001). Risperidone and tardive dyskinesia. Int J Geriatr Psychiatry 16:541-542.
51. Mullen A (2000). Risperidone and tardive dyskinesia: a case of blepharospasm. Aust NZ J Psychiatry 34:879-880.
52. Naidu PS, Singh A, Kulkarni SK (2004). Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin. Pharmacology 70: 59-67.
53. O'Hara P, Brugha TS, Lesage A, Wing J (1993). New findings on tardive dyskinesia in a community sample. Psychol Med 23:453-465.
54. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. (2000). Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 57:249-258.
55. Robinson AD, McCreadie RG (1986). The Nithsdale schizophrenia survey. V. Follow-up of tardive dyskinesia at 312 years. Br J Psychiatry 149:621-623.
56. Rosenquist KJ, Walker SS, Ghaemi SN (2002). Tardive dyskinesia and ziprasidone. Am J Psychiatry 159:1436.
57. Sacchetti E, Valsecchi P (2003). Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. Int Clin Psychopharmacol 18:357-359.
58. Sachdev P (2004). Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust NZ J Psychiatry 38: 445-449.
59. Santone G, Contani P, Giuliani S, Marchesi GF (1997). Tardive dyskinesia remission during risperidone therapy. Clin Drug Invest 14:502-506.
60. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487.
61. Sharma V (2003). Treatment-emergent tardive dyskinesia with quetiapine in mood disorders. J Clin Psychopharmacol 23:415-417.
62. Simpson GM (2000). The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 61 (suppl 4):39-44.
63. Spivak M, Smart M (2000). Tardive dyskinesia from low-dose risperidone. Can J Psychiatry 45:202.
64. Suzuki E, Obata M, Yoshida Y, Miyaoka H (2002). Tardive dyskinesia with risperidone and anticholinergics. Am J Psychiatry 159:1948.
65. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM (1994). Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 55 (suppl B):102-106.
66. Tarsy D, Granacher R, Bralower M (1977). Tardive dyskinesia in young adults. Am J Psychiatry 134:1032-1034.
67. Tarsy D (2000). Tardive dyskinesia: current treatment options in neurology. Curr Treat Options Neurol 2:205-214.
68. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS (1997). The interrelationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curacao Extrapyramidal Syndromes Study II. Schizophr Res 26:235-242.
69. Vieta E, Goikolea JM, Corbella B, Benabarre A, Reinares M, Martinez G, et al. (2001). Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 62:818-825.
70. Woods SW (1999). Olanzapine and tardive dyskinesia. Br J Psychiatry 175:391-392.